Photo from Rasha Aboelhassan/LinkedIn
Sep 17, 2024, 15:16
Key takeaways from ESMO24 Oral session on early stage breast cancer by Rasha Aboelhassan
Rasha Aboelhassan shared a post on LinkedIn:
”Mini oral session today. Early stage breast cancer conclusion and deeper thinking:
- Younger patients are in higher risk with less survival.
- It’s better to give ovarian suppression with AI to improve 5 years survival outcomes.
- Is it better to add ribociclib with AI as adjuvant therapy? Maybe.
- But unfortunately, younger patients are having less adherence to treatment.
Kivin Kalinsiky. Discussion:
- Tumor biopsy is different in younger patients, and there are more challenges upcoming.
To get better survival, please remember: more is not always better, you need to do more conversations with your patient.”
Source: Rasha Aboelhassan/LinkedIn
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35
Dec 3, 2024, 09:23
Dec 3, 2024, 09:20